비교리스트

 카트 문의
시장보고서
상품코드
1559723

세계의 엑소좀 시장

Exosomes
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 196 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

엑소좀 세계 시장은 2030년까지 3억 7,700만 달러에 달할 전망

2023년에 1억 7,840만 달러로 추정된 엑소좀 세계 시장은 2030년에는 3억 7,700만 달러에 이를 것으로 예측되며, 분석 기간 2023-2030년의 CAGR은 11.3%로 성장할 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 암 질환 적응증은 CAGR 16.5%로 성장을 지속하고, 분석 기간 종료 시에는 9억 2,160만 달러에 달할 것으로 예측됩니다. 신경 퇴행성 질환 적응증 부문의 성장률은 분석 기간 동안 CAGR 13.7%로 추정됩니다.

미국 시장은 4,550만 달러로 추정, 중국은 CAGR 10.5%로 성장 예측

미국의 엑소좀 시장은 2023년 4,550만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간 2023-2030년 CAGR을 10.5%로 2030년까지 예측 시장 규모 6,070만 달러에 달할 것으로 예측되고 있습니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 9.6%와 9.2%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 8.3%로 성장할 것으로 예측됩니다.

세계 엑소좀 시장 - 주요 동향과 촉진요인 요약

엑소좀은 생명공학과 의료에 어떤 혁명을 일으키고 있는가?

엑소좀은 거의 모든 세포 유형에서 분비되는 미세한 소포로 생명공학과 의학에서 변혁의 도구가 되고 있으며, 세포간 커뮤니케이션에서 중요한 역할을 하고 있습니다. 직경 30 내지 150 나노미터의 이 나노크기 입자는 단백질, 지질, 핵산(RNA 등)의 적재를 원래의 세포로부터 다른 세포로 운반합니다. 분자정보를 전달하는 이 과정을 통해 엑소좀은 면역반응, 조직수리, 암 등 질환의 진행 등 다양한 생리학적·병리학적 과정을 제어할 수 있습니다. 엑소좀은 생물학적 정보의 천연 운반체로서의 역할을 담당하기 때문에 현재 진단용 바이오마커나 치료제로서의 가능성이 널리 연구되고 있습니다.

최근 엑소좀은 질병의 진단과 치료에 혁명을 일으킬 수 있다고 주목받고 있습니다. 유전자 발현을 조절하는 마이크로 RNA와 같은 분자를 운반하고 전달하는 능력은 표적 약물 전달 시스템의 이상적인 후보입니다. 합성 약물 전달과는 달리, 엑소좀은 생체적합성이 있어 면역 반응을 일으키지 않고 체내를 순환할 수 있기 때문에 특정 조직이나 세포에 치료제를 전달하기 위한 매력적인 비히클이 되고 있습니다. 게다가 엑소좀은 혈액뇌 장벽과 같은 생물학적 장벽을 통과할 수 있어 지금까지 신경질환에서의 약물 전달의 과제가 되었습니다. 그 결과, 엑소좀에 기초한 치료법은 암 치료, 신경퇴행성 질환, 재생의료 등의 분야에서 연구되고 있습니다. 정밀의료의 미래를 재구성할 가능성을 지닌 엑소좀은 질병의 진단, 모니터링, 치료에 대한 혁신적인 접근법의 최전선에 있습니다.

왜 엑소좀은 표적 치료와 진단의 미래로 여겨지고 있는가?

엑소좀은 표적 치료를 촉진하고 질병의 조기 발견을 위한 바이오마커로서의 독특한 능력으로 의료 분야에서 큰 관심을 끌고 있습니다. 엑소좀의 주요 이점 중 하나는 유래 세포에 따라 특정 세포 및 조직을 표적으로 하는 자연적인 능력입니다. 이 표적화 능력은 엑소좀에 존재하는 표면 단백질과 수용체를 기반으로 하며, 이는 특정 세포 유형에 인식되고 흡수됩니다. 이 특성은 엑소좀이 약물, 유전자 치료 및 기타 치료 분자를 환부 세포에 직접 전달하는 데 이상적인 수단이 되어 오프타겟 효과를 최소화하고 전신 부작용의 위험을 줄입니다. 예를 들어, 암 치료에서 특정 면역세포로부터 유래된 엑소좀은 항암제를 종양 세포로 직접 운반하도록 설계될 수 있고, 건강한 조직을 온존하면서 치료 효과를 향상시킬 수 있습니다.

진단학에 있어서는 엑소좀은 다양한 질환, 특히 암, 심혈관계 질환, 신경퇴행성 질환의 비침습적 바이오마커로서 크게 기대되고 있습니다. 엑소좀은 혈액, 소변, 타액과 같은 체액으로 방출되기 때문에 쉽게 채취하고 분석할 수 있으며 질병과 관련된 분자 서명을 감지할 수 있습니다. 예를 들어, 암세포는 종양의 존재를 확인하고, 질병의 진행을 추적하며, 치료에 대한 반응을 모니터링하는 데 사용할 수 있는 특정 단백질과 RNA를 포함하는 엑소좀을 방출합니다. 엑소좀을 이용한 이 "리퀴드 바이옵시" 접근법은 전통적인 조직 생검보다 침습성이 낮아 질병의 조기 발견과 보다 맞춤 치료 전략을 가능하게 합니다. 또한, 엑소좀을 이용한 진단은 환자의 체내에서 일어나는 분자 변화를 실시간으로 알 수 있어 보다 역동적이고 신속한 의료 개입에 대한 길을 열 수 있습니다. 이러한 진보는 왜 엑소좀이 표적 치료와 질병의 조기 발견의 미래에 필수적인 태세를 갖추었는지를 명확하게 보여줍니다.

엑소좀 연구의 의학과 바이오테크놀러지에서의 응용과 혁신의 확산이란?

엑소좀 연구의 확대 응용은 암 치료에서 재생 의료, 백신 개발에 이르기까지 의학과 생명공학의 여러 분야에서의 혁신을 촉진하고 있습니다. 암연구에 있어서는 암세포가 엑소좀을 사용하여 주위 조직과 커뮤니케이션을 취하고 질병의 확산을 촉진하기 때문에 종양의 진행과 전이에 있어서의 엑소좀의 역할이 연구되고 있습니다. 이러한 종양 유래의 엑소좀을 차단하여 조사함으로써 연구자는 암 진행의 분자 메커니즘에 대한 통찰을 얻어 새로운 치료 표적을 확인할 수 있습니다. 게다가 엑소좀 기반의 전달 시스템은 화학요법제와 유전자 치료제를 종양 부위로 직접 수송하고 기존의 암 치료에 따른 독성을 완화하기 위해 개발되고 있습니다. 이 접근법은 건강한 세포에 대한 손상을 최소화하면서 암 치료의 효과를 높일 것으로 기대됩니다.

엑소좀은 재생의료 분야에서도 파문을 넓히고 있습니다. 특히 중간엽 줄기세포(MSC) 유래의 엑소좀은 조직의 복원과 재생을 촉진하는 능력을 입증합니다. 이러한 엑소좀은 세포 증식, 혈관신생(신생혈관 형성), 항염증 반응을 자극하는 생리활성 분자를 가지며, 상해, 만성 상처, 퇴행성 질환의 치료에 유용합니다. 사실, MSC 유래 엑소좀은 골관절염, 심근경색, 척수 손상 등의 치료법으로 연구되고 있습니다. 면역거부반응이나 종양성 등의 과제에 직면하는 종래의 줄기세포 치료와는 달리, 엑소좀을 이용한 치료는 치유나 조직 재생에 보다 안전하고 적당한 접근을 제공합니다.

엑소좀의 또 다른 획기적인 응용은 백신 개발입니다. 연구자들은 감염에 대한 면역 반응을 자극하는 데 사용할 수있는 항원의 전달 차량으로 엑소 좀의 사용을 찾고 있습니다. 엑소좀은 면역세포와 자연스럽게 상호작용하기 때문에 바이러스나 박테리아의 항원을 운반하도록 설계할 수 있어 살아있는 병원체를 반입하지 않고 신체에 면역반응을 일으킬 수 있습니다. 백신에 대한 이러한 새로운 접근법은 특히 암과 HIV, 심지어 COVID-19와 같은 신흥 감염의 위협에 맞서 싸우는 데 더 효과적이고 능동적 인 면역 요법을 개발할 가능성이 있습니다. 생물학적 장벽을 넘어 분자 정보를 수송하는 엑소좀의 범용성에 의해 폭넓은 치료·진단 용도의 유망한 플랫폼이 되어 의료 분야에 혁명을 가져옵니다.

엑소좀 시장의 성장을 가속하는 요인은 무엇인가?

엑소좀 시장의 성장은 개인화된 의료에 대한 수요 증가, 생명공학의 발전, 질병의 조기 진단에 대한 관심 증가와 같은 몇 가지 중요한 요인에 의해 야기됩니다. 가장 중요한 촉진요인 중 하나는 유전적, 분자적, 환경적 요인에 따라 개별 환자에 맞게 치료를 하는 정밀의료에 대한 관심 증가입니다. 엑소좀은 특정 분자 카고를 운반하고 그것을 표적 세포에 직접 전달하는 능력을 가지며, 이 접근법에 이상적인 도구입니다. 더 많은 치료법이 환자 특이적이 됨에 따라, 엑소좀과 같은 정교한 전달 시스템의 요구는 계속 증가하고 시장 성장에 박차를 가할 것으로 보입니다. 암치료, 신경 퇴행성 질환, 재생의료에 있어서의 엑소좀에 근거한 치료의 응용은 급속히 확대되고 있어 지금까지 치료가 곤란했던 병태에 새로운 희망을 가져오고 있습니다.

엑소좀 시장 성장의 또 다른 요인은 엑소좀의 분리, 특성화 및 조작을 가능하게 하는 생명공학의 급속한 발전입니다. 초원심분리, 마이크로플루이딕스공학, 크기 배제 크로마토그래피 등의 엑소좀 분리를 위한 새로운 방법을 통해 생물학적 액체로부터 엑소좀을 고순도, 고수율로 채취하는 것이 용이해졌습니다. 이러한 기술적 진보는 엑소좀에 기초한 진단법 및 치료법의 개발을 촉진하여 임상에서의 사용을 보다 친숙하게 하고 있습니다. 게다가 차세대 시퀀싱(NGS)과 질량분석과 같은 분자 프로파일링 기술의 향상으로 연구자들은 보다 높은 정밀도로 엑소좀 내용물을 분석할 수 있게 되어 새로운 바이오마커와 치료 표적의 발견으로 이어지고 있습니다.

비침습적 진단을 중시하는 경향이 강해지고 있는 것도 엑소좀 시장을 견인하는 큰 요인입니다. 조직 생검과 같은 전통적인 진단 방법은 침습적이며 고통스럽고 비싸기 때문에 혈액과 소변과 같은 체액에서 질병 바이오 마커를 검출하는 엑소 좀을 사용하여 액체 생체에 대한 관심이 높아지고 있습니다. 이러한 비침습적 진단 도구로의 이동은 조기 진단이 환자의 결과를 개선하는데 매우 중요한 암의 발견에 특히 중요합니다. 헬스케어 시스템이 조기 발견과 예방의료를 우선시함에 따라, 엑소좀 기반의 진단제는 의료 현장에서 더 큰 역할을 할 것으로 예상됩니다. 또한 FDA, EMA 등의 규제기관이 엑소좀을 기반으로 한 치료법 및 진단법의 인가를 개시함에 따라 시장이 급속히 확대되고 제약회사와 생명공학신흥기업 모두에서 많은 투자가 모여 됩니다.

결론적으로 엑소좀 시장은 정밀의료, 생명공학의 진보, 혁신적인 진단·치료 솔루션에 대한 요구의 융합에 의해 크게 성장하는 태세가 갖추어지고 있습니다. 암에서 신경 퇴행성 질환에 이르기까지 광범위한 질병의 치료에서 엑소좀의 가능성이 조사에 의해 밝혀지고 있는 가운데 시장은 더욱 확대와 혁신을 이룰 것으로 보입니다. 엑소좀은 세포 전체에 분자 메시지를 전달하고 표적 요법을 제공하는 독특한 능력을 통해 보다 효과적이고 개인화된 치료와 질병의 조기 발견에 대한 희망을 제공하고 차세대 의료의 기초가 된다 예상됩니다.

조사 대상 기업 예(전 46건)

  • Aruna Bio
  • Avalon GloboCare Corp
  • CD Bioparticles
  • Diagenode SA
  • EVerZom
  • Evox Therapeutics
  • ExoCoBio
  • Exosome Diagnostics, Inc.
  • Kinetic River Corp.
  • Lifeasible

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

JHS 24.09.27

Global Exosomes Market to Reach US$377.0 Million by 2030

The global market for Exosomes estimated at US$178.4 Million in the year 2023, is expected to reach US$377.0 Million by 2030, growing at a CAGR of 11.3% over the analysis period 2023-2030. Cancer Disease Indication, one of the segments analyzed in the report, is expected to record a 16.5% CAGR and reach US$921.6 Million by the end of the analysis period. Growth in the Neurodegenerative Diseases Indication segment is estimated at 13.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$45.5 Million While China is Forecast to Grow at 10.5% CAGR

The Exosomes market in the U.S. is estimated at US$45.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$60.7 Million by the year 2030 trailing a CAGR of 10.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.6% and 9.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global Exosomes Market - Key Trends and Drivers Summarized

How Are Exosomes Revolutionizing Biotechnology and Medicine?

Exosomes, tiny vesicles secreted by nearly all cell types, have become a transformative tool in biotechnology and medicine, playing a critical role in intercellular communication. These nano-sized particles, ranging from 30 to 150 nanometers in diameter, carry a cargo of proteins, lipids, and nucleic acids (such as RNA) from their cell of origin to other cells. This process of transferring molecular information enables exosomes to regulate a variety of physiological and pathological processes, including immune responses, tissue repair, and the progression of diseases such as cancer. Due to their role as natural carriers of biological information, exosomes are now being studied extensively for their potential as diagnostic biomarkers and therapeutic agents.

In recent years, exosomes have gained attention for their potential to revolutionize the diagnosis and treatment of diseases. Their ability to carry and deliver molecules like microRNAs, which regulate gene expression, makes them ideal candidates for targeted drug delivery systems. Unlike synthetic drug delivery methods, exosomes are biocompatible and can circulate in the body without triggering immune responses, which makes them attractive vehicles for delivering therapeutic agents to specific tissues or cells. Furthermore, exosomes can cross biological barriers, such as the blood-brain barrier, which has historically posed a challenge for drug delivery in neurological conditions. As a result, exosome-based therapies are being explored in areas such as cancer treatment, neurodegenerative diseases, and regenerative medicine. With their potential to reshape the future of precision medicine, exosomes are at the forefront of innovative approaches to disease diagnosis, monitoring, and treatment.

Why Are Exosomes Considered the Future of Targeted Therapies and Diagnostics?

Exosomes are garnering significant interest in the medical field due to their unique ability to facilitate targeted therapies and serve as biomarkers for early disease detection. One of the key advantages of exosomes is their natural ability to target specific cells or tissues, depending on the cell of origin. This targeting ability is based on surface proteins and receptors present on the exosomes, which allows them to be recognized and absorbed by specific cell types. This property makes exosomes an ideal vehicle for delivering drugs, gene therapies, or other therapeutic molecules directly to the affected cells, minimizing off-target effects and reducing the risk of systemic side effects. In cancer therapy, for example, exosomes derived from certain immune cells can be engineered to carry anticancer drugs directly to tumor cells, potentially improving the efficacy of the treatment while sparing healthy tissue.

In diagnostics, exosomes hold great promise as non-invasive biomarkers for various diseases, particularly cancers, cardiovascular diseases, and neurodegenerative disorders. Since exosomes are released into bodily fluids such as blood, urine, and saliva, they can be easily harvested and analyzed to detect molecular signatures associated with disease. For example, cancer cells release exosomes that contain specific proteins and RNAs that can be used to identify the presence of tumors, track disease progression, and monitor the response to treatments. This "liquid biopsy" approach using exosomes offers a less invasive alternative to traditional tissue biopsies, allowing for earlier detection of diseases and more personalized treatment strategies. Furthermore, exosome-based diagnostics can potentially provide real-time insights into the molecular changes occurring in a patient’s body, paving the way for more dynamic and responsive healthcare interventions. These advancements underscore why exosomes are poised to become integral to the future of both targeted therapies and early disease detection.

What Are the Expanding Applications and Innovations in Exosome Research Across Medicine and Biotechnology?

The expanding applications of exosome research are fueling innovations in several fields of medicine and biotechnology, ranging from cancer therapy to regenerative medicine and vaccine development. In cancer research, exosomes are being explored for their role in tumor progression and metastasis, as cancer cells use exosomes to communicate with surrounding tissues and promote the spread of the disease. By intercepting and studying these tumor-derived exosomes, researchers can gain insights into the molecular mechanisms of cancer progression and identify new therapeutic targets. Additionally, exosome-based delivery systems are being developed to transport chemotherapy drugs or gene therapies directly to tumor sites, reducing the toxicity associated with traditional cancer treatments. This approach promises to enhance the effectiveness of cancer therapies while minimizing damage to healthy cells.

Exosomes are also making waves in the field of regenerative medicine. Mesenchymal stem cell (MSC)-derived exosomes, in particular, have demonstrated the ability to promote tissue repair and regeneration. These exosomes carry bioactive molecules that stimulate cell proliferation, angiogenesis (the formation of new blood vessels), and anti-inflammatory responses, making them valuable in treating injuries, chronic wounds, and degenerative diseases. In fact, MSC-derived exosomes are being investigated as a potential treatment for conditions like osteoarthritis, myocardial infarction, and spinal cord injuries. Unlike traditional stem cell therapies, which face challenges such as immune rejection and tumorigenicity, exosome-based therapies offer a safer and more targeted approach to healing and tissue regeneration.

Another groundbreaking application of exosomes is in vaccine development. Researchers are exploring the use of exosomes as delivery vehicles for antigens, which could be used to stimulate an immune response against infectious diseases. Since exosomes naturally interact with immune cells, they can be engineered to carry viral or bacterial antigens, prompting the body to produce an immune response without introducing a live pathogen. This novel approach to vaccines holds potential for developing more effective and targeted immunotherapies, especially in combating diseases like cancer, HIV, and even emerging infectious threats such as COVID-19. The versatility of exosomes in transporting molecular information across biological barriers makes them a promising platform for a wide range of therapeutic and diagnostic applications, revolutionizing the field of medicine.

What Factors Are Driving the Growth of the Exosome Market?

The growth in the exosome market is driven by several key factors, including the rising demand for personalized medicine, advancements in biotechnology, and the increasing focus on early disease diagnosis. One of the most significant drivers is the growing interest in precision medicine, where treatments are tailored to the individual patient based on their genetic, molecular, and environmental factors. Exosomes, with their ability to carry specific molecular cargo and deliver it directly to target cells, are ideal tools for this approach. As more therapies become patient-specific, the need for sophisticated delivery systems like exosomes will continue to rise, fueling growth in the market. The application of exosome-based therapies in cancer treatment, neurodegenerative diseases, and regenerative medicine is expanding rapidly, offering new hope for conditions that have been historically difficult to treat.

Another factor contributing to the growth of the exosome market is the rapid advancement of biotechnologies that enable the isolation, characterization, and manipulation of exosomes. New methods for exosome isolation, such as ultracentrifugation, microfluidics, and size exclusion chromatography, have made it easier to harvest exosomes from biological fluids with high purity and yield. These technological advancements are facilitating the development of exosome-based diagnostics and therapies, making them more accessible for clinical use. Additionally, improvements in molecular profiling techniques, such as next-generation sequencing (NGS) and mass spectrometry, are enabling researchers to analyze the contents of exosomes with greater accuracy, leading to the discovery of novel biomarkers and therapeutic targets.

The growing emphasis on non-invasive diagnostics is another major factor driving the exosome market. Traditional diagnostic methods, such as tissue biopsies, can be invasive, painful, and expensive, leading to increased interest in liquid biopsies that use exosomes to detect disease biomarkers from bodily fluids like blood or urine. This shift towards non-invasive diagnostic tools is particularly important in cancer detection, where early diagnosis is crucial for improving patient outcomes. As healthcare systems prioritize early detection and preventive care, exosome-based diagnostics are expected to play a larger role in medical practice. Furthermore, as regulatory agencies such as the FDA and EMA begin to approve exosome-based therapies and diagnostics, the market is set to expand rapidly, attracting significant investments from both pharmaceutical companies and biotech startups.

In conclusion, the exosome market is poised for significant growth, driven by the convergence of precision medicine, biotechnology advancements, and the need for innovative diagnostic and therapeutic solutions. As research into exosomes continues to reveal their potential in treating a wide range of diseases, from cancer to neurodegenerative conditions, the market will see further expansion and innovation. With their unique ability to carry molecular messages across cells and deliver targeted therapies, exosomes are set to become a cornerstone of next-generation medicine, offering hope for more effective, personalized treatments and earlier disease detection.

Select Competitors (Total 46 Featured) -

  • Aruna Bio
  • Avalon GloboCare Corp
  • CD Bioparticles
  • Diagenode SA
  • EVerZom
  • Evox Therapeutics
  • ExoCoBio
  • Exosome Diagnostics, Inc.
  • Kinetic River Corp.
  • Lifeasible

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Exosomes - Global Key Competitors Percentage Market Share in 2024 (E)
    • Global Economic Update
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Emerging Role of Exosomes in Diagnostic and Therapeutic Applications Driving Market Growth
    • Increasing Investment in Exosome-based Research for Cancer and Neurodegenerative Diseases
    • Market Trends Toward Development of Exosome-based Biomarkers
    • Consumer Demand for Non-invasive Diagnostic Options Fueling Exosome Innovations
    • Future Directions: Harnessing Exosomes for Targeted Drug Delivery
    • Impact of Nanotechnology on Exosome Engineering and Functionalization
    • Development of Exosome-based Therapeutics for Rare Diseases
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World 7-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Neurodegenerative diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 4: World 7-Year Perspective for Neurodegenerative diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Cardiovascular diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World 7-Year Perspective for Cardiovascular diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Infectious diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World 7-Year Perspective for Infectious diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 10: World 7-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World 7-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World 7-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 15: World Exosomes Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Exosomes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Exosomes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 18: USA Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 19: USA 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • CANADA
    • TABLE 22: Canada Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: Canada 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 24: Canada Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Canada 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • JAPAN
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 28: Japan Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Japan 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • CHINA
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 30: China Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: China 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 32: China Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: China 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • EUROPE
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Europe 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Europe 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Exosomes by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe 7-Year Perspective for Exosomes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
  • FRANCE
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 40: France Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: France 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 42: France Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: France 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • GERMANY
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Germany 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 46: Germany Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Germany 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • ITALY
    • TABLE 48: Italy Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Italy 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Italy 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • UNITED KINGDOM
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 52: UK Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: UK 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 54: UK Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: UK 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 58: Rest of Europe Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Rest of Europe 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Asia-Pacific 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 64: Rest of World Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Rest of World 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 66: Rest of World Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Rest of World 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제